SCHEMBL5481693

SCHEMBL5481693

COCC(=O)Nc1ccc(CC(=O)Nc2ncc(C(C)C)s2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 13/20 0.67
CCNE1 P24864 12/20 0.67
CDK5 Q00535 12/20 0.67
SMN1; SMN2 Q16637 3/20 0.67
ALDH1A1 P00352 3/20 0.67
CCNT1 O60563 1/20 0.67
CDK1 P06493 1/20 0.67
CDK4 P11802 1/20 0.67
CCNB1 P14635 1/20 0.67
CCNA2 P20248 1/20 0.67
CCND1 P24385 1/20 0.67
CDK7 P50613 1/20 0.67
CDK9 P50750 1/20 0.67
CCNH P51946 1/20 0.67
MNAT1 P51948 1/20 0.67
CDK5R1 Q15078 1/20 0.67
HPGD P15428 2/20 0.51
PSEN1 P49768 1/20 0.45
PSEN2 P49810 1/20 0.45
APH1B Q8WW43 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5726979 0.89 CDK2 (0.65) CDK2CCNE1CDK5SMN1; SMN2ALDH1A1
SCHEMBL5476972 0.87 CDK2 (0.88) CDK2CCNE1CDK5SMN1; SMN2ALDH1A1
SCHEMBL5726464 0.87 CDK2 (0.72) CDK2CCNE1CDK5SMN1; SMN2ALDH1A1
SCHEMBL5726576 0.86 CDK2 (0.70) CDK2CCNE1CDK5SMN1; SMN2ALDH1A1
SCHEMBL5480558 0.86 CDK2 (0.73) CDK2CCNE1CDK5SMN1; SMN2ALDH1A1
SCHEMBL5726471 0.85 CDK2 (0.72) CDK2CCNE1CDK5SMN1; SMN2ALDH1A1
SCHEMBL5484289 0.84 CDK2 (0.67) CDK2CCNE1CDK5SMN1; SMN2ALDH1A1
SCHEMBL5835602 0.84 CDK5 (0.73) CDK2CCNE1CDK5SMN1; SMN2ALDH1A1
SCHEMBL5481249 0.83 CDK2 (0.66) CDK2CCNE1CDK5SMN1; SMN2ALDH1A1
SCHEMBL7645385 0.83 CDK2 (0.66) CDK2CCNE1CDK5SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1204649-B1 ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-10-17 EP claimed
US-20050004120-A1 Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents PHARMACIA ITALIS S.P.A. (IT) 2005-01-06 US claimed
US-6784198-B1 2-(ARYLMETHYL-CARBONYLAMINO)-1,3-THIAZOLE DERIVATIVES; CDK/CYCLIN KINASE INHIBITORY ACTIVITY PHARMACIA ITALIA S.P.A. (IT) 2004-08-31 US claimed
CN-1425009-A Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-06-18 CN claimed
EP-1204649-A1 ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS Pharmacia Italia S.p.A. (IT) 2002-05-15 EP claimed
WO-2001014353-A1 ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA ITALIA, S.P.A. (IT) 2001-03-01 WO claimed
US-6114365-A Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN S.P.A. (IT) 2000-09-05 US claimed
EP-1204649-B1 ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-10-17 EP disclosed
US-20050004120-A1 Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents PHARMACIA ITALIS S.P.A. (IT) 2005-01-06 US disclosed
US-6784198-B1 2-(ARYLMETHYL-CARBONYLAMINO)-1,3-THIAZOLE DERIVATIVES; CDK/CYCLIN KINASE INHIBITORY ACTIVITY PHARMACIA ITALIA S.P.A. (IT) 2004-08-31 US disclosed
CN-1425009-A Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-06-18 CN disclosed
EP-1204649-A1 ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS Pharmacia Italia S.p.A. (IT) 2002-05-15 EP disclosed
WO-2001014353-A1 ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA ITALIA, S.P.A. (IT) 2001-03-01 WO disclosed
US-6114365-A Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN S.P.A. (IT) 2000-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004120-A1 Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents CCAR2, BCL2, ROS1 CDK2 26/4885CCNE1 513/4885CDK5 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.